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Prolonged co-treatment with HGF 
sustains epithelial integrity and 
improves pharmacological rescue of 
Phe508del-CFTR
Ana M. Matos  1,2, Andreia Gomes-Duarte1,2, Márcia Faria1,2,3, Patrícia Barros1,2, 
Peter Jordan1,2, Margarida D. Amaral2 & Paulo Matos1,2
Cystic fibrosis (CF), the most common inherited disease in Caucasians, is caused by mutations in 
the CFTR chloride channel, the most frequent of which is Phe508del. Phe508del causes not only 
intracellular retention and premature degradation of the mutant CFTR protein, but also defective 
channel gating and decreased half-life when experimentally rescued to the plasma membrane (PM). 
Despite recent successes in the functional rescue of several CFTR mutations with small-molecule 
drugs, the folding-corrector/gating-potentiator drug combinations approved for Phe508del-CFTR 
homozygous patients have shown only modest benefit. Several factors have been shown to contribute 
to this outcome, including an unexpected intensification of corrector-rescued Phe508del-CFTR PM 
instability after persistent co-treatment with potentiator drugs. We have previously shown that acute 
co-treatment with hepatocyte growth factor (HGF) can significantly enhance the chemical correction 
of Phe508del-CFTR. HGF coaxes the anchoring of rescued channels to the actin cytoskeleton via 
induction of RAC1 GTPase signalling. Here, we demonstrate that a prolonged, 15-day HGF treatment 
also significantly improves the functional rescue of Phe508del-CFTR by the VX-809 corrector/VX-770 
potentiator combination, in polarized bronchial epithelial monolayers. Importantly, we found that HGF 
treatment also prevented VX-770-mediated destabilization of rescued Phe508del-CFTR and enabled 
further potentiation of the rescued channels. Most strikingly, prolonged HGF treatment prevented 
previously unrecognized epithelial dedifferentiation effects of sustained exposure to VX-809. This 
was observed in epithelium-like monolayers from both lung and intestinal origin, representing the 
two systems most affected by adverse symptoms in patients treated with VX-809 or the VX-809/VX-
770 combination. Taken together, our findings strongly suggest that co-administration of HGF with 
corrector/potentiator drugs could be beneficial for CF patients.
Mutations in the CFTR gene cause cystic fibrosis (CF), the most common inherited disease in Caucasians1. 
They can alter the synthesis, processing, function, and half-life of CFTR, the main chloride channel expressed 
apically at the plasma membrane (PM) of epithelial cells2. Respiratory failure, derived from severe airway 
obstruction, inflammation, and recurrent infections, is the most prevalent mortality cause in CF2. Although CF 
is still incurable (mean survival of ~40 years), the last decade brought remarkable progress towards personal-
ized CF treatments, with the development of small-molecule drugs targeting frequent CFTR mutations3,4. The 
proof-of-principle was Ivacaftor (VX-770), a potentiator drug that relieved CF symptoms in patients bearing 
mutations (e.g., Gly551Asp) that impair CFTR channel activity (4–8% of patients)5. Soon after, Lumacaftor 
(VX-809), a pharmacological chaperone, in combination with VX-770, was approved by the Food and Drug 
Administration (FDA) and European Medicines Agency (EMA)6 for patients homozygous for the most common 
mutation – Phe508del (~40% of patients), which impairs CFTR folding and trafficking7. In phase II trials, the 
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VX-809/VX-770 combination (at the higher administered doses) significantly improved the percentage predicted 
forced expiratory volume in one second (FEV1) by a mean of 6% in patients homozygous for Phe508del-CFTR, 
decreased sweat chloride concentration by ~10 mmol/L, and decreased pulmonary exacerbations in the treatment 
groups8. Data from subsequent phase III trials revealed improvements in predicted FEV1 ranging from 2.6–4.0% 
and a clear, 30–39% decrease in the rate of pulmonary exacerbations, significantly reducing hospitalization and 
the use of intravenous antibiotics in the treatment groups9. The VX-809/VX-770 drug combination has now been 
used in patients since 2015, and several subsequent studies of its long-term usage indicate that it does benefit CF 
patients, although several cases of off-target side-effects have been reported, the most frequent being respiratory 
and gastrointestinal manifestations10–12.
Despite the reported benefits, the results from these studies fell below initial expectations and experimen-
tal evidence emerged to, at least partially, explain the limited clinical improvements observed in patients. 
For instance, it was shown that persistent exposure to potentiator drugs, particularly VX-770, results in a 
dose-dependent reversal of VX-809-mediated CFTR correction in Phe508del-CFTR homozygous primary air-
way cell cultures13,14. This was due to destabilization and increased turnover of the rescued protein, resulting in 
its reduced functional expression at the cell surface. A posterior study, however, argued that at clinically relevant 
concentrations (below 1 μM), continuous exposure to VX-770 does not inhibit the rescue of Phe508del-CFTR 
by VX-80915. In addition, it was also observed that Pseudomonas aeruginosa reduces Phe508del-CFTR function 
in cells treated either with VX-809 alone or with the VX-809/VX-770 combination16,17. Since 85% of adult CF 
patients are colonized with P. aeruginosa, these data suggest that infection with these bacteria may also contribute 
to a reduction in the therapeutic efficacy of these drugs.
Importantly, we and others showed that the intrinsically reduced stability of rescued Phe508del-CFTR at the 
cells’ PM (less than 10% that of wt-CFTR)18,19 -due to its deficient anchoring to the actin cytoskeleton and target-
ing by the peripheral protein quality control - could be a major obstacle to its pharmacological correction19–22. 
However, we showed that acute treatment with hepatocyte growth factor (HGF) can increase Phe508del-CFTR 
stability and retention at the PM20. HGF acts via RAC1 GTPase to promote the PDZ-mediated interaction of 
Phe508del-CFTR with NHERF1 and ezrin adaptor proteins, favouring the channel’s anchoring to the actin 
cytoskeleton20,21. Notably, co-treatment with HGF enhanced over 3-fold the functional restoration efficacy of 
chemical correctors such as corr-4a (C4) and C3, by preventing internalization of rescued Phe508del-CFTR from 
the PM20.
Here, we investigated whether HGF treatment would enhance the functional correction of Phe508del-CFTR 
by the VX-809/VX-770 drug combination. For this, we used in vitro epithelium-like cellular models to deter-
mine what would be the cellular and functional consequences of a prolonged, phase II trial duration-consistent, 
combined treatment with VX-809/VX-770 and HGF. We found that prolonged co-administration of HGF signif-
icantly increased the Phe508del-CFTR functional rescue by VX-809/VX-770 in bronchial polarized monolayers, 
also preventing VX-770-mediated destabilization of PM-rescued channels. Intriguingly, we show that prolonged 
co-treatment with HGF strengthens the integrity of bronchial and intestinal epithelium-like cellular cultures, 
suppressing yet unreported cellular dedifferentiation effects of continued exposure to VX-809, which may relate 
to the drug’s adverse effects.
Our data strongly suggests that HGF co-administration might be beneficial for CF patients, particularly in 
the initial weeks of treatment, and in patients with severe lung disease, who suffered from more frequent and 
pronounced adverse drug effects.
Results
HGF enhances functional rescue of Phe508del-CFTR by acute VX-809/VX-770 co-treatment. 
We previously demonstrated that the functional correction of Phe508del-CFTR by corrector C4 in CFBE cells 
can be enhanced up to 3-fold by co-treatment with HGF20. Thus, we asked if HGF treatment would also enhance 
Phe508del-CFTR functional rescue when co-administered with the VX-809/VX-770 drug combination. To 
address this question we used the well-established halide-sensitive YFP (HS-YFP) functional assay21,23,24. Briefly, 
CFBE cells co-expressing Phe508del-CFTR and the halide-sensitive YFP-F46L/H148Q/I152L mutant23 (HS-YFP) 
were incubated in duplicates for 48 h with either DMSO, 10 μM of C4, or 3 μM VX-809. One of each replicate 
was co-treated with 50 ng/mL of HGF for the last 24 h. One additional replicate was added for the VX-809/HGF 
treatment, which was incubated with 25 μM of CFTR inhibitor 172 (inh172), 15 min prior to the assay. Cells were 
then stimulated for 30 min in PBS with 5 μM forskolin (Fsk), and either 20 μM genistein (Gen) or 10 μM VX-770. 
Analysis of HS-YFP fluorescence decay showed that HGF enhanced the functional response of C4-rescued 
Phe508del-CFTR by ~2.2-fold in this assay (Fig. 1a,b), in agreement with our previous findings using other meth-
ods20. Importantly, we also observed an equivalent increase (~2.5-fold) in CFTR function with VX-809/HGF 
co-treatment, versus VX-809 treatment alone, upon acute stimulation with Fsk and VX-770. Moreover, confirm-
ing a CFTR-specific response, co-treatment with inh172 reversed this effect (Fig. 1b).
Next, we tested whether the effect of HGF co-treatment was sustained in polarized CFBE cells. 
CFBE-Phe508del/HS-YFP cells were polarized in transwell, 0.4 μm PET filter inserts (24-well size), until they 
reached a transepithelial electrical resistance (TEER) of ≥600 Ω. Cells, in duplicate or triplicate filters, were 
treated with DMSO or 3 μM VX-809 for 48 h. Two of the VX-809 replicates were co-treated with 50 ng/mL of 
HGF for the last 24 h. One of these replicates was additionally incubated for 15 min with 25 μM of inh172 prior to 
the iodide influx assay. TEER was monitored for all conditions and no significant variations were observed over 
time (Fig. 2a).
To measure fluorescence decay after CFTR stimulation we developed an in-house setup (see Methods and 
Fig. 2b) that forms a chamber on top of a glass slide. The setup can be positioned on the confocal microscope stage 
and loaded with transwell inserts containing CFBE-Phe508del/HS-YFP polarized cells. This places the polarized 
cells within the focal length of a 10× objective (Fig. 2b), allowing live imaging acquisition. Thus, XZ confocal 
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fluorescence images were collected continuously after the rapid (≤1 s) apical addition of iodide (I−) together 
with 5 μM Fsk, with or without 10 μM VX-770, and with or without 25 μM of inh172, as indicated (Fig. 2c, 
and see also Supplementary Movies SM1–SM5 for representative YFP quenching recordings). Calculation of 
initial iodide influx rates from the fluorescence decay curves (Fig. 2d) clearly showed that HGF co-treatment 
Figure 1. HGF treatment improves functional rescue of Phe508del-CFTR by chemical correctors. (a) 
Fluorescence decay curves of the iodide influx assay. CFBE-Phe508del cells stably expressing the YFP-halide 
sensor were treated, as indicated, for 48 h with 10 μM corr-4a (C4) or 3 μM VX-809, in the presence or 
absence of 50 ng/ml of HGF for the last 24 h. Cells were then stimulated with 5 μM forskolin (Fsk) and either 
20 μM genistein (Gen) or 10 μM VX-770, in the presence or absence of 25 μM CFTR inhibitor 172 (inh172). 
Fluorescence was recorded continuously in a microplate reader, first for 10 s (baseline) and then for 110 s after 
the rapid (≤1 s) addition of isomolar PBS, in which Cl− was replaced by I−. Fluorescence (F) was plotted over 
time as percentage of fluorescence at time 0 (F0). Data are means ± SEM of three independent assays. (b) Iodide 
influx rates calculated by fitting the curves to the exponential decay function to derive the maximal slope that 
corresponds to initial influx of I− into the cells23. Data are means ± SEM of three independent assays. §p < 0.01 
relative to DMSO; #p < 0.001.
Figure 2. HGF treatment improves functional rescue of Phe508del-CFTR by VX-809/VX-770 in polarized 
CFBE cells. (a) Variation in TEER of polarized CFBE-Phe508del/HS-YFP cells treated for 48 h as indicated. (b) 
Schematic representation of the in-house setup used to record HS-YFP fluorescence decay in polarized cells. 
(c) Fluorescence decay curves of the iodide influx assay in polarized CFBE-Phe508del/HS-YFP cells, treated for 
48 h with either DMSO or 3 μM of VX-809 in the presence or absence of HGF for the last 24 h, as indicated, and 
stimulated acutely with 10 μM of VX-770 (acVX-770). Fluorescence (F) was plotted over time as percentage of 
fluorescence at time 0 (F0). Data are means ± SEM of three independent assays. (d) Iodide influx rates calculated 
as in Fig. 1b. Data are means ± SEM of three independent assays. *p < 0.01; #p < 0.001.
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significantly increased the Phe508del-CFTR functional rescue by the combination of VX-809-mediated correc-
tion and VX-770 acute potentiation. Moreover, consistent with the results from non-polarized cells, this func-
tional increase was 2.9-fold higher than with VX-809/VX-770 treatment alone and was completely suppressed by 
the presence of inh172 (Fig. 2d). Western blot (WB) analysis from these filters showed that HGF treatment pro-
duced a small increase in rescued Phe508del-CFTR mature C band steady-state levels (Fig. 3a), but this was not 
sufficient to justify the roughly 3-fold increase in CFTR-dependent ion transport (Fig. 2d). We, therefore, immu-
nostained replicate filters to detect the localization of CFTR (Fig. 3b). We found that, more than enhancing the 
overall levels of CFTR in these cells, HGF promoted the accumulation of 2-times more rescued Phe508del-CFTR 
at the apical membrane (Fig. 3c), shifting to ~2.6-fold the ratio of CFTR apical/basolateral distribution (Fig. 3d). 
These data were confirmed by conventional cell surface protein biotinylation assays, where HGF produced a 
Figure 3. HGF treatment promotes apical localization of VX-809-rescued Phe508del-CFTR in polarized CFBE 
cells. (a) WB analysis of whole cell lysates from polarized CFBE cells treated for 48 h with either DMSO or 3 μM 
of VX-809 in the presence or absence of HGF for the last 24 h, as indicated, and stimulated acutely with 10 μM 
of VX-770 (acVX-770). Shown are representative images of CFTR and Ki-67 immunoblots together with bar 
plots of band intensity quantification, normalized to DMSO (means ± SEM), from three independent assays. 
Tubulin was used as a loading normalizer in band intensity quantification. (b) Immunofluorescence staining 
of polarized CFBE-Phe508del cells treated as in (a), were stained with anti-CFTR/Alexa 488, phalloidin-
TRITC and DAPI, and analysed by confocal microscopy. Shown are overlay images (upper images) as well as 
isolated CFTR-staining (green channel) representative of the indicated treatment conditions. Yellow trace lines 
exemplify the method used for CFTR signal quantification. Actin signal was used as a guide to define the apical 
(AP) and basolateral (BL) membrane regions (dotted lines) that were used to quantify CFTR signal intensity 
(solid lines). AP, BL and Total (BL + AP) signal intensities in cells treated or not with HGF and VX-809/acVX-
770 are plotted in (c) and the ratio between AP and BL signal intensities in (d). Data indicates mean ± SEM 
of signals from at least 30 cells analysed in each of the three independent experiments. White arrows indicate 
apical shift in CFTR localization upon HGF treatment. White horizontal bar represents 10 μm. #p < 0.001 
(e) Conventional cell surface protein biotinylation assays of CFBE cells treated as in (a). Fold change in total 
(WCL) and PM (Surface)-rescued Phe508del-CFTR band C levels were quantified by WB densitometry and are 
indicated below the respective panels.
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1.4-fold increase in the total levels of VX-809-rescued band C but a 3.3 fold increment in the levels of CFTR at the 
PM (Fig. 3e). Both results are consistent with the enhancement of the channel’s anchoring and retention at the cell 
surface that we previously described for HGF co-treatment in C4-corrected CFBE-Phe508del cells20.
Prolonged co-treatment with HGF sustains enhanced Phe508del-CFTR functional rescue by 
VX-809/VX-770 drug combination. The hyperactivity of the HGF/c-MET pathway has been observed 
in numerous neoplasms, including non-small-cell lung carcinomas25. Prolonged or continuous activity of the 
c-MET receptor by mutation, gene amplification, or altered signalling properties, leads to excessive cell prolifer-
ation and is related to neoplastic disease development and progression26.
Thus, we used WB to analyse the levels of Ki-67 protein in the lysates of polarized CFBE-Phe508del cells, 
treated as above. Ki-67 is commonly and reliably used as a pro-proliferative marker for human cells and 
tumours27. It is present during all active phases of the cell cycle, being markedly increased in proliferating 
cell populations but only residual or absent in resting (non-dividing) cells28. Here, we observed no significant 
change in Ki-67 abundance in polarized CFBE-Phe508del cells after 24 h of HGF treatment (Fig. 3a). Therefore, 
we decided to analyse the effects of a more prolonged treatment with HGF, both regarding its enhancement of 
VX-809/VX-770 action and its effect on the differentiation and proliferation of polarized CFBE epithelia. We 
chose to extend our treatment for a period of 15 days, since this would be within the time frame of a phase II trial8. 
Moreover, we also considered previous studies reporting that the prolonged exposure to VX-770 concentrations 
above 1 μM inhibited the functional rescue of Phe508del-CFTR by VX-80913,15. Thus, CFBE-Phe508del cells were 
polarized in filter inserts to a minimum TEER value of 600 Ω and exposed, for 15 days, to either DMSO (control), 
DMSO + 50 ng/ml HGF, 3 μM VX-809, 3 μM VX-809 + 50 ng/ml HGF, 0.5 μM VX-770, 0.5 μM VX-770 + 3 μM 
VX-809, or 0.5 μM VX-770 + 3 μM VX-809 + 50 ng/ml HGF. TEER was monitored at days 3, 7, 11, and 15, and 
the culture medium replaced by fresh medium containing the same compound combinations. A clear decrease in 
relative TEER values (normalized to day 0) was observed from day 3 onwards in cells treated with VX-809 alone, 
and in cells treated with VX-809/VX-770 after day 7, when compared to DMSO (Fig. 4a). Notably, co-treatment 
with HGF prevented relative TEER decrease in CFBE cells treated either with VX-809 alone or in combination 
with VX-770 (Fig. 4a). WB analysis of these cells showed a significant ~1.5-fold increase in CFTR C band levels in 
cells treated with HGF alone (DMSO + HGF), compared to DMSO, consistent with an enhanced apical retention 
of the residual Phe508del-CFTR rescued by prolonged exposure to low DMSO concentrations (Fig. 4b).
Prolonged VX-809 treatment produced a significant ~2.5-fold increase in mature C band levels, compared 
to DMSO. Co-treatment with VX-809 and VX-770 also produced a significant increase in C band abundance, 
though slightly lower (~2.1-fold) than with VX-809 alone (Fig. 4b). Importantly, the effect of HGF was additive 
to the prolonged treatment with VX-809 alone (from ~2.5 to ~3.4-fold, over DMSO) and, remarkably, it appears 
to protect VX-809-rescued Phe508del-CFTR from the destabilization caused by VX-770 co-treatment, allowing 
for C band levels ~3.7-fold greater than DMSO-treated cells (Fig. 4b). No significant variations in B band levels 
were observed between treatments.
Next, we tested the double and triple 15-day treatments in CFBE cells co-expressing Phe508del-CFTR and 
the HS-YFP sensor. As before, fluorescence decay in these cells was measured after CFTR stimulation with 5 μM 
Fsk. Treatment with the VX-809/VX-770 combination produced a significant ~3.6-fold increase in iodide influx 
over DMSO treated cells (Fig. 4c,d), although in absolute values this activity was roughly 2.5 times lower than that 
achieved with 48 h of VX-809 treatment followed by acute 10 μM VX-770 potentiation (see Fig. 2d). Consistent 
with the observed impact on the apical retention of rescued CFTR, co-treatment with HGF more than tripled 
(~3.3-fold) the effect of the VX-drugs alone (Fig. 4d), a result that was reverted by the presence of 25 μM inh172. 
Notably, the effect of HGF co-treatment was increased by ~1.7-fold when 20 μM Gen and 5 μM Fsk were added 
acutely (Fig. 4c and d), consistent with further potentiation of apically rescued CFTR.
Remarkably, prolonged treatment with HGF, alone or in combination with the VX-drugs, did not increase 
the steady-state levels of Ki-67, which indicates no change in the proliferative behaviour of these cells (Fig. 4b). 
Of note, there was a small (1.5-fold) but significant decrease in the levels of Ki-67 upon prolonged exposure to 
VX-770 alone.
Co-treatment with HGF prevents depolarization of CFBE epithelium-like monolayers after pro-
longed exposure to VX-809. The decrease in TEER observed in polarized monolayers exposed to VX-809 
for more than 3 to 7 days (see Fig. 4a) led us to use WB to analyse the effects of the prolonged treatment on epi-
thelial integrity and differentiation markers (Fig. 5a). While E-cadherin levels showed no significant variations, a 
significant ~2-fold decrease in Zonula Occludens-1 (ZO-1) steady-state abundance was detected in both condi-
tions where cells were treated with VX-809 (Fig. 5a).
Once again, co-treatment with HGF seemed to revert this effect in both cases, bringing ZO-1 levels back to 
those observed in DMSO control cells. In fact, incubation with HGF alone produced a small (~1.5-fold) but sig-
nificant increase in ZO-1 levels, which might represent compensation for VX-809-induced ZO-1 downregulation. 
These effects were also observed through confocal microscopy after ZO-1 immunostaining (Fig. 5b). Moreover, 
we could confirm that treatment with HGF alone stimulated ZO-1 localization to sub-apical, focal cell-cell con-
tacts, consistent with an enhancement of tight-junction (TJ) maturation. This observation, together with the clear 
morphologic improvement in cell polarity (as seen through phalloidin staining of the actin cytoskeleton - Fig. 5b) 
and the increase in relative TEER (Fig. 4a), is indicative that the prolonged HGF treatment of bronchial epithelial 
cells has a pro-differentiation effect. In contrast, treatment with VX-809 alone led to a clear loss of ZO-1 at TJ sites 
that, based on the actin cytoskeleton morphology, was accompanied by a loss of cellular polarity (Fig. 5b) consist-
ent with the pronounced decrease in TEER observed after 15 days of treatment (Fig. 4a). Combination of VX-809 
and VX-770 had a similar effect on ZO-1 levels and distribution at day 15, albeit with a lower impact on cellular 
morphology and TEER levels relative to VX-809 alone (Figs 4a and 5b, respectively), possibly related to the 
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observed delay in TEER decline induced by VX-770 co-treatment (Fig. 4a). Importantly, co-incubation with HGF 
clearly reverted VX-809-induced CFBE depolarization, particularly in the triple treatment combination, where 
the cellular phenotype closely resembled that of DMSO-treated cells (Fig. 5b). We also analysed the steady-state 
levels of cytokeratin 8 (CK8) and 18 (CK18) after the 15-day treatment. Interestingly, we found that whereas the 
prolonged treatment with VX-809 significantly decreased the steady-state abundance of CK18, either alone or in 
combination with VX-770 (Fig. 5a), CK8 levels increased in response to both VX-809 and VX-770. Moreover, 
the combination of the two drugs had an additive effect, increasing CK8 levels ~2.3-fold over DMSO-treated cells 
(Fig. 5a). Importantly, co-treatment with HGF returned CK8/CK18 expression to near control levels, even in the 
presence of the VX-809/VX-770 combination (Fig. 5a,c,d).
HGF treatment prevents depolarization of colorectal epithelial cells after prolonged exposure 
to VX-809/VX-770 treatment. Several cases of off-target effects have been reported for VX-809/VX-770 
combination treatment, most of which result in pulmonary and gastrointestinal complications29. Given the 
observed effects in the polarization of bronchial epithelial cells, we questioned the consequences of a prolonged 
treatment with the VX-drugs, alone and in combination with HGF, on the polarity and expression of epithelial 
differentiation markers in cells from gastrointestinal origin.
The human intestinal Caco-2 cell line has been extensively used over the last decades as a model for the 
intestinal epithelium, namely to study the regulation and function of wild-type CFTR, which these cells express 
endogenously and at high levels (see Fig. 6a)30–34. Originally obtained from a human colon adenocarcinoma, 
these cells undergo a process of spontaneous differentiation in culture that leads to the formation of a cell mon-
olayer, resembling a simple columnar epithelium (Fig. 6a), which exhibits several morphological and functional 
characteristics of mature enterocytes34,35. Thus, as before, we polarized Caco-2 cells in filter inserts to a TEER 
of ~600 Ω and exposed them for 15 days to either DMSO (control), DMSO + 50 ng/ml HGF, 3 μM VX-809, 
Figure 4. Prolonged HGF treatment improves functional rescue of Phe508del-CFTR by the VX-809/VX-770 
combination without stimulating proliferation of polarized CFBE cells. (a) Variation in TEER of polarized 
CFBE-Phe508del cells treated for 15 days with DMSO, HGF (50 ng/ml), VX-809 (3 μM), VX-770 (0.5 μM) 
alone or in the indicated combinations. Conditions leading to significant or near-significant TEER variations 
are indicated. (b) WB analysis of whole cell lysates from polarized CFBE-Phe508del cells treated as in (a). 
Shown are representative images of CFTR and Ki-67 immunoblots together with bar plots of band intensity 
quantification, normalized to DMSO (means ± SEM) from three independent assays. Tubulin was used as a 
loading normalizer in band intensity quantification. (c) Fluorescence decay curves of iodide influx assays in 
polarized CFBE-Phe508del/HS-YFP cells treated as in (a) and stimulated with 5 μM Fsk alone or together 
with 20 μM of Gen in the presence or absence of 25 μM of inh172, as indicated. Fluorescence (F) was plotted 
over time as percentage of fluorescence at time 0 (F0). (d) Iodide influx rates calculated as in Fig. 1b. Data are 
means ± SEM of three independent assays. *p < 0.05, &p < 0.005, and #p < 0.001.
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3 μM VX-809 + 50 ng/ml HGF, 0.5 μM VX-770, 0.5 μM VX-770 + 3 μM VX-809, or 0.5 μM VX-770 + 3 μM 
VX-809 + 50 ng/ml HGF. As for CFBE cells, TEER was monitored at days 3, 7, 11, and 15, and the cell medium 
was replaced by fresh medium containing the same compound combinations.
A significant decrease in relative TEER (normalized to day 0) was observed from day 3 onwards in cells treated 
with VX-809, either alone or in combination with VX-770, when compared to DMSO-treated cells (Fig. 6b). 
Notably, in both situations, co-treatment with HGF obviated the decrease in relative TEER (Fig. 6b). Moreover, 
treatment with HGF alone seemed to promote Caco-2 differentiation, significantly increasing TEER values 
when compared to control cells. WB analysis showed that HGF alone promoted a ~2-fold increase in ZO-1 and 
E-cadherin levels, two markers of epithelial differentiation (Fig. 6c). In contrast, prolonged exposure to VX-809, 
alone or in combination with VX-770, led to a nearly 2-fold decrease in the steady-state abundance of ZO-1, 
similar to the observed with CFBE cells. In both cases, co-incubation with HGF reverted ZO-1 decrease by the 
VX-drugs (Fig. 6c). Consistently, immunostaining of Caco-2 cells showed that prolonged exposure to VX-drugs 
results in a clear dedifferentiation of epithelial-like morphology, with abrogation of ZO-1 expression and locali-
zation, leading to an apparent loss of TJs integrity (Fig. 6d). Moreover, in contrast to what was observed in CFBE 
cells, prolonged treatment of Caco-2 cells with either VX-809 or VX-770 alone, resulted in a clear (>1.6-fold) 
decrease of E-cadherin steady-state levels, producing a nearly 3-fold decrease when both drugs were combined 
(Fig. 6c). This effect on E-cadherin was also readily seen by confocal microscopy after immunostaining of Caco-2 
cells (Fig. 6e). Notably, co-treatment with HGF prevented E-cadherin downregulation by the VX-drug com-
bination (Fig. 6c), restoring TEER values (Fig. 6b), E-cadherin localization to cell-cell contacts, and polarized 
Figure 5. HGF co-treatment prevents dedifferentiation of polarized CFBE cells after prolonged exposure 
to VX-809. Polarized CFBE-Phe508del cells were treated for 15 days with DMSO, HGF (50 ng/ml), VX-809 
(3 μM), or VX-770 (0.5 μM), alone or in the indicated combinations. (a) WB analysis of whole cell lysates. 
Shown are representative images of immunoblots for ZO-1, E-cadherin, CK8, and CK18 together with bar 
plots of band intensity quantification, normalized to DMSO (means ± SEM) from three independent assays. 
Histone H2B was used as a loading normalizer in band intensity quantification. (b–d) Immunofluorescence 
staining of polarized CFBE-Phe508del cells, treated as in (a), were stained with phalloidin-TRITC, DAPI, and 
either anti-ZO-1/Alexa 488 (b), anti-CK8/Alexa 488 (c), or anti-CK18/Alexa 488 (d), and analysed by confocal 
microscopy. Shown are overlay images representative of the indicated treatment conditions. White horizontal 
bars represent 10 μm. *p < 0.05.
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epithelium morphology (Fig. 6e). Interestingly, Caco-2 cells did not show any significant variation in CK8 expres-
sion in response to the different treatments (Fig. 6c). In addition, while a small decrease in CK18 levels was 
observed upon prolonged exposure to VX-770 (not statistically significant), HGF treatment produced a signifi-
cant ~1.6-fold increase in CK18 expression, which was sustained in the presence of both VX-drugs (Fig. 6c). This 
effect was also clearly observed in immunostained cells (Fig. 6f).
HGF and the VX-809/VX-770 combination have opposite effects on Ki-67 expression in Caco-2 
cells. Analysis of Ki-67 steady-state abundance in polarized Caco-2 cells revealed that whereas stand-alone 
exposure to HGF significantly increased the levels of this pro-proliferative marker (~1.6-fold), incubation with 
the VX-770 had the opposite effect, resulting in a ~1.8-fold decrease in Ki-67 expression (Fig. 7). Significantly, the 
triple combination (VX-809/VX-770/HGF) resulted in Ki-67 levels close to those of DMSO-treated cells, consist-
ent with a reversal of VX-770- induced Ki-67 downregulation by HGF co-treatment (Fig. 7).
Figure 6. HGF co-treatment prevents dedifferentiation of polarized Caco-2 cells after prolonged exposure 
to the VX-809/VX-770 drug combination. (a) Caco-2 colorectal cells were polarized to a TEER above 600 Ω, 
stained with phalloidin-TRITC, DAPI, and anti-CFTR/Alexa 488, and analysed by confocal microscopy. (b) 
Variation in TEER of polarized Caco-2 colorectal cells treated for 15 days with DMSO, HGF (50 ng/ml), VX-809 
(3 μM), or VX-770 (0.5 μM), alone or in the indicated combinations. Conditions leading to significant TEER 
variations are indicated. (c) WB analysis of whole cell lysates from polarized Caco-2 cells treated as in (b). 
Shown are representative images of immunoblots for ZO-1, E-cadherin, CK8, and CK18 together with bar plots 
of band intensity quantification, normalized to DMSO (means ± SEM) from three independent assays. Histone 
H2B was used as a loading normalizer in band intensity quantification. (d–f) Immunofluorescence staining of 
polarized Caco-2 cells, treated as in (b), with phalloidin-TRITC, DAPI, and either anti-ZO-1/Alexa 488 (d), 
anti-E-cadherin/Alexa 488 (e), or anti-CK18/Alexa 488 (f) and analysed by confocal microscopy. Shown are 
overlay images representative of the indicated treatment conditions. White horizontal bars represent 10 μm. 
*p < 0.05; #p < 0.01.
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Discussion
In this study we investigated three major questions: (1) whether HGF treatment would enhance the functional 
correction of Phe508del-CFTR by the VX-809/VX-770 drug combination; (2) whether the effect would be sus-
tained in polarized, epithelium-like bronchial cell monolayers; and (3) what would be the cellular and functional 
consequences of a phase II trial duration-consistent, 15-day long combined treatment with VX-809/VX-770 and 
HGF.
We found, similar to what we had previously shown for corrector C420, that 24 h of co-treatment with HGF 
increased by roughly 3-fold the functional correction of Phe508del-CFTR that can be achieved in CFBE cells by 
a 48 h treatment with VX-809 followed by acute potentiation with VX-770. Significantly, this result was consist-
ently observed in both polarized and non-polarized cells. Moreover, we found evidence that HGF treatment also 
significantly enhanced the apical accumulation of VX-809-rescued Phe508del-CFTR in polarized CFBE cells, 
not by varying the total abundance of the protein but by increasing the ratio of its apical/basolateral distribution, 
indicating an enhanced retention of the rescued channels at the cell’s apical membrane. This is consistent with 
our previous findings that HGF treatment stimulates the anchoring of apical CFTR to the actin cytoskeleton via 
stimulation of RAC1-mediated PIP2 production and the formation of a CFTR/NHERF1/Ezrin/F-actin macro-
molecular complex20. Importantly, we found that the effect of HGF treatment was still observable after prolonged, 
15-day co-treatment with HGF, VX-809 and 0.5 μM VX-770. Notably, prolonged exposure to this low VX-770 
concentration still decreased VX-809-mediated rescue of Phe508del-CFTR. This is consistent with previous find-
ings that sustained exposure to VX-770, even at concentrations below 1 μM, can interfere with Phe508del-CFTR 
cell surface stability, promoting its PM removal, accelerating its internalization and markedly increasing its 
turnover rate13,14. Also of note, we show here that HGF can protect VX-809-rescued Phe508del-CFTR from 
VX-770 induced destabilization. This is in agreement with our previous findings that HGF treatment prevents the 
internalization of rescued Phe508del-CFTR by promoting its anchoring to the sub-apical cytoskeleton20,21, and 
with our current observation that HGF exposure leads to the apical accumulation of VX-809/VX-770-rescued 
CFTR. Moreover, whereas the functional output of VX-809-rescued Phe508del-CFTR after prolonged treat-
ment with 0.5 μM VX-770 was considerably lower than that achieved by acute potentiation with 10 μM of the 
drug, co-treatment with HGF more than compensated for this decrease, reaching levels of CFTR-mediated ion 
transport 30% higher than those of the acute treatment. In addition, this effect was nearly doubled by acute 
co-stimulation with genistein, which is consistent with previous reports that VX-809-rescued CFTR channels at 
the apical membrane are poorly potentiated by therapeutic range VX-770 concentrations15, making them recep-
tive to further potentiation13,15. Consistently, a recent study showed that potentiators, such as genistein and cur-
cumin, additively enhanced forskolin-induced swelling of VX-809/VX-770-treated intestinal organoids derived 
from biopsies of Phe508del homozygous patients36. Together with our results, these data suggest that genistein 
and/or curcumin could be used in combination with HGF to synergistically increase CFTR-mediated chloride 
secretion in the treatment of CF.
The VX-809/VX-770 combination has now been used in patients since 2015, and several cases of off-target 
side-effects have been reported29. These adverse effects can manifest in up to 40% of treated patients, with the vast 
majority (~80%) being pulmonary but with some patients (~24%) also manifesting gastrointestinal symptoms, 
including diarrhoea and nausea12. Our findings suggest that these manifestations may, at least partially, be related 
to a previously unreported epithelial dedifferentiation effect resulting from prolonged exposure to VX-809. This 
is of particular interest since we show that HGF treatment was highly effective in preventing VX-809-induced 
dedifferentiation of bronchial and colorectal epithelium-like monolayers. In polarized bronchial epithelia cells, 
Figure 7. Prolonged HGF and VX-770 treatments have opposite effects on Ki-67 levels in polarized Caco-2 
cells. Polarized Caco-2 colorectal cells were treated for 15 days with DMSO, HGF (50 ng/ml), VX-809 (3 μM), 
or VX-770 (0.5 μM), alone or in the indicated combinations. Shown are representative WB images of whole 
cell lysates probed with anti-Ki-67 and anti-Tubulin antibodies. Bar plot shows quantification of Ki-67 band 
intensity, normalized to DMSO (means ± SEM) from three independent assays. Tubulin was used as a loading 
normalizer in band intensity quantification.
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we demonstrated that HGF restored ZO-1 levels, TJ localization and TEER values. It is interesting to note that 
VX-770 also had a partially protective effect on VX-809-induced dedifferentiation of CFBE cells, delaying TEER 
reduction by 3 days when compared to VX-809 stand-alone treatment. This protective effect of VX-770 may 
relate to its impact on Ki-67 levels. We observed that prolonged exposure to VX-770 alone nearly depleted Ki-67 
levels in CFBE cells. Absence of Ki-67 is associated with resting cells that have entered a ‘quiescent’ state due to 
the absence of extrinsic pro-proliferative signals37–39. Our results indicate that prolonged exposure to low concen-
trations of VX-770 may somehow mimic this state, partially desensitizing bronchial epithelial cells from depo-
larization by VX-809.
HGF also prevented VX-809-induced dedifferentiation of colorectal Caco-2 polarized cells. For this cell type, 
however, although prolonged treatment with VX-770 also significantly decreased Ki-67 abundance, it was not 
sufficient to constrain the depolarizing effect of VX-809 when used in combination. In fact, the VX-drug combi-
nation produced the most pronounced TEER decrease in Caco-2 cells, which by the end of the treatment reached 
below 65% of the initial value (corresponding to TEER values under 400 Ω). This may relate to our observation 
that stand-alone treatment with either drug produced a significant decrease of E-cadherin steady-state levels, 
which was additive, reaching nearly 3-fold when both drugs were combined. Indeed, decreased expression of 
E-cadherin and ZO-1 adhesion molecules are well known markers of colorectal cell dedifferentiation and strongly 
correlate with epithelial-mesenchymal transition (EMT) in colorectal cancers40–42. Importantly, despite inducing 
a small but significant increase in Ki-67 levels when used alone, prolonged treatment with HGF had a marked 
pro-differentiation effect on polarized colorectal cell monolayers; it stimulated ZO-1 and E-cadherin expres-
sion, promoted their localization to cell-cell contacts, prevented their downregulation by VX-drugs, and restored 
TEER values and epithelial morphology. Moreover, the opposite effects of HGF and VX-drugs on Ki-67 expres-
sion apparently compensate for each other, producing a net result of Ki-67 levels close to those of control cells.
We also monitored the levels of CK8 and CK18. These intermediate filament components are typically 
co-expressed as the primary keratin pair in simple epithelial cells, but tissue-specific variations in their expres-
sion are often associated with cancer-related cellular dedifferentiation and EMT43,44. In lung cancers, for instance, 
increased CK8 expression is correlated with increased invasiveness of tumour cells in vitro and in vivo45. In con-
trast, the role of CK18 upregulation is less clear, having been described associated with lung cancer progression46, 
as well as with better differentiation and decreased tumour malignancy47. Here we found that the dedifferentia-
tion of CFBE cells induced by prolonged exposure to VX-809 associated with a significant increase in CK8 levels 
and a decrease in CK18 expression. Interestingly, whereas prolonged exposure to VX-770 alone also increased 
CK8 abundance, being additive with VX-809 in the combination treatment, it did not, however, decrease the 
levels of CK18. Rather, co-treatment with VX-770 reduced the downregulation of CK18 by VX-809, which con-
sidering that the co-treatment delayed TEER decrease in CFBE cells, is consistent with the reported effect of CK18 
in preventing dedifferentiation of lung epithelial cells47. Again, co-treatment with HGF attenuated the variations 
in CK8/18 levels induced by the VX-drugs, consistent with its effect in restoring epithelial morphology. Notably, 
in colorectal Caco-2 cells, neither VX-809 nor VX-770, alone or in combination, induced significant variations 
in CK8/18 levels. Loss of CK8 expression has been associated with hyperproliferation of colorectal cells48,49, but 
despite elevating Ki-67 levels, prolonged HGF treatment produced no significant change in CK8 levels in polar-
ized Caco-2 cells. However, HGF significantly upregulated CK18 levels. Upregulation of CK18 levels has been 
associated with promotion of enterocytic differentiation of Caco-2 cells, via Notch signalling49, and this is con-
sistent with previous reports showing that exposure to HGF accelerates Caco-2 cell differentiation by stimulating 
the metabolic and structural events accompanying this process50.
In summary, we found that, as expected, HGF treatment also significantly enhanced the functional rescue of 
Phe508del-CFTR by acute treatment with the VX-809/VX-770 drug combination. Moreover, we further demon-
strated that this enhancement was sustained in polarized bronchial epithelial monolayers after prolonged, 15-day 
HGF co-treatment with VX-809 and low, therapeutic-compatible VX-770 doses, reaching functional rescue lev-
els higher than those achieved by acute potentiation with high VX-770 concentrations. Importantly, we found 
that HGF treatment also prevented VX-770-mediated destabilization of rescued Phe508del-CFTR and enabled 
further potentiation of the rescued channels by genistein, indicating that HGF co-treatment would also favour 
previously suggested combination therapies using multiple correctors36. Most striking, we observed that rather 
than promoting cell scattering and proliferation, a well-known effect of HGF on polarized MDCK cells51, pro-
longed HGF treatment of polarized airway cells actually prevented the previously unrecognized epithelial ded-
ifferentiation effects of prolonged exposure to VX-809. While the physiologic relevance of these observations 
cannot be fully ascertained through the use of in vitro models, they strongly suggest that there may be a potential 
gain in addressing in vivo and ex vivo (in patient-derived tissues), the effects of adding HGF to current combi-
national drug therapies. Moreover, while polarized CFBE and Caco2 monolayers do not fully recapitulate the 
properties of differentiated epithelia in vivo, these models have been extensively used to study the mechanisms 
of CF disease and, in the case of CFBE cells, for the development and characterization of several CFTR modu-
lator drugs13–15,52,53, where they have been shown to respond similarly to primary airway cells20,52,53. Thus, our 
finding of previously unreported potentially dedifferentiative effects of prolonged exposure to VX-809 in these 
cells highlights the importance of using more extended treatment periods, while assessing the cellular effects of 
new CF-modulator drugs in pre-clinical studies. It should be mentioned that a next-generation CFTR corrector, 
VX-661 (Tezacaftor), in combination with VX-770, has proven to be equally effective and better tolerated than 
VX-809 in clinical trials54–56, and recently received FDA approval for the treatment of patients, aged 12 years and 
older, homozygous for the Phe508del mutation or having at least one CFTR mutation that is responsive to the 
drug combination, based on in vitro data and/or clinical evidence57. However, it should be noted that the destabi-
lizing effect of long exposure to VX-770 therapeutic-range concentrations on VX-661-rescued Phe508del-CFTR 
channels was even more pronounced than that observed for VX-80914. This suggests that, if supported by further 
in vivo studies, the potentially protective effect of HGF co-treatment against VX-770-induced destabilization of 
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apically rescued Phe508del-CFTR could also be beneficial for VX-661-treated patients. This might be even more 
applicable in the case of patients with severe lung disease (predicted FEV1 < 40%) that were not included in the 
initial VX-661/VX-770 trials54–56, but for which recent clinical data, following treatment with VX-809/VX-770, 
revealed a considerably higher frequency and severity of therapy-related respiratory adverse events (particu-
larly in the first weeks of treatment) and lessened clinical benefit10,58,59. Supportive of a potential application of 
HGF in the CF setting, several studies in animal models have provided strong evidence that HGF administration 
potently mitigates the effects of acute and chronic lung injuries caused by oxidative stress and inflammation60. 
Encouragingly, some of these studies have also shown that HGF had a protective effect when given either simulta-
neously with or after prolonged lung-damaging stimuli, suggesting that HGF pro-regenerative action is effective 
during both the initiation and the progressive phase of lung disease61.
Taken together, our findings emphasise the critical importance of assessing the cellular effects of prolonged 
exposure to investigational CF drugs in pre-clinical studies and provide compelling evidence for the potential 
benefit of including HGF in CF combination therapies, alerting the scientific community to the need and rele-
vance of further in vivo studies with this physiological factor in the context of CF. Supporting the plausibility of 
such studies, the intravenous/systemic administration of recombinant HGF protein has been well tolerated in 
phase I/II clinical trials for liver regeneration62 and it is currently under trial for its regenerative effects in several 
other conditions63,64.
Methods
Cell culture, polarization and treatment. CFBE41o- cells stably expressing Phe508del-CFTR (CFBE-
Phe508del cells) (a kind gift from JP Clancy, University of Alabama USA) were maintained in minimal essential 
medium (MEM) supplemented with L-glutamine, Earle’s salts, 10% (v/v) foetal bovine serum (FBS) and 2 μg/
ml puromycin, whereas Caco-2 cells were maintained in RPMI supplemented with 10% (v/v) FBS (all reagents 
were from Life Technologies Invitrogen Corporation). All cell lines were cultured at 37 °C under 5% CO2 and 
regularly checked for the absence of mycoplasm infection. CFBE-Phe508del cells stably co-expressing the YFP-
F46L/H148Q/I152L halide sensor (CFBE-Phe508del/HS-YFP CFBE cells) were generated by transfection with 
LipofectAMINE 2000 followed by 3-week selection with 0.4 mg/ml hygromycin B (both from Thermo Scientific). 
Fluorescent cells were then sorted (FACSAriaIII, BD Biosciences) and expanded maintaining selective pressure 
with 0.4 mg/ml hygromycin B.
Cell monolayers were polarized in transwell, collagen IV coated, porous (0.4 μm) PET filter inserts (Ø 6.4 mm, 
from Falcon – Thermo Fisher Scientific), in medium supplemented with 2.5% FBS, until they reached a transe-
pithelial electrical resistance (TEER) above 600 Ω, as measured with a Chopstick Electrode (STX2 from WPI®). 
Cells were then treated for the indicated periods, with DMSO (Sigma Aldrich) or the described concentrations of 
recombinant human HGF (Santa Cruz Biotechnology), corr4a (C4; CF Foundation modulator library), VX-809, 
VX-770 (both Selleck Chemicals), CFTR inhibitor-172 (inh-172; CFFT USA), forskolin (Fsk) or genistein (Gen) 
(both from Sigma-Aldrich). All stock solutions were made 103 times concentrated, dissolved in DMSO.
Fluorescent Iodide Influx Assay /Halide-sensitive YFP-based functional assay. CFTR activity was 
determined using Phe508del/HS-YFP CFBE cells seeded in 8-well chamber slides or 96-well microplates, or 
polarized in transwell filter inserts, as described above. Cells were treated with the indicated compound concen-
trations for the described time periods. Cells were washed with PBS and incubated for 30 min in PBS containing 
compounds for CFTR stimulation/inhibition (Fsk, VX-809, VX-770, Gen and inh172) at the indicated concentra-
tions. Non-polarized cells were then transferred either to a microplate reader (Tecan® Infinite M200) (excitation: 
505 nm and emission: 535 nm) or to a Leica TCS-SPE confocal microscope for time-lapse analysis. Each well was 
assayed individually for iodide influx by recording fluorescence continuously (500 ms/point) for 10 s (baseline) 
and then for 110 s after the rapid (<1 s) addition of isomolar PBS in which 137 mM Cl− was replaced by I− (PBSI, 
final NaI concentration in the well: 100 mM). Assays were performed at room temperature. After background 
subtraction, cell fluorescence recordings were normalized for the initial average value measured before addition 
of I−.
For polarized cells in transwell filter inserts, we developed an in-house setup to assess HS-YFP fluorescence 
decay by confocal microscopy. Briefly, a Ø 16 mm × 17 mm-high × 1mm-thick polypropylene ring was sealed on 
top of a glass slide to form a PBS-containing chamber (Fig. 2b), which can be positioned on the confocal micro-
scope stage. This setup allows the transwell inserts, containing Phe508del/HS-YFP CFBE polarized cells, to be 
placed inside the slide chamber within the focal length of a 10× objective. The apical side medium is replaced 
by 100 μl PBS, and the insert secured to the chamber through a Ø 0.5 mm steel tubing clamp that also allows the 
addition of I− and CFTR stimulators to the apical side of the polarized cell layer (Fig. 2b). XZ fluorescence images 
were collected continuously with a 3 Airy pinhole at 500 ms intervals, first for 10 s (baseline), and then for 110 s 
after the rapid (≤1 s) apical pumping of 350 μl of PBSI, containing 5 μM Fsk with or without 10 μM VX-770, and 
with 25 μM of inh172 for some experimental conditions. Quantification of fluorescence decay was performed on 
at least 30 individual cells per filter, using ImageJ (NIH) as previously described21.
Immunoblotting, immunofluorescence and confocal microscopy. Samples were analysed by immu-
noblotting as previously described20,21. Additional antibodies used for WB were: mouse anti-CFTR clone 596 
(obtained through the UNC CFTR antibody distribution program sponsored by CFFT), mouse anti-α-Tubulin 
clone B-5-1-2 (Sigma-Aldrich), mouse-anti-E-cadherin (Transduction Laboratories), mouse-anti-CK18 
(Millipore), rabbit-anti-ZO-1, rabbit-anti-CK8, rabbit-anti-Ki-67 and rabbit-anti-H2B (all from Santa Cruz 
Biotechnology). Primary antibodies were detected using secondary, peroxidase-conjugated antibodies (Bio-Rad) 
followed by ECL. For densitometric analysis of WB bands, x-rays films were digitalized and images analysed with 
ImageJ software (NIH).
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For immunofluorescence analysis, cells grown on filters were fixed with 4% formaldehyde, washed with PBS, 
permeabilized with 0.2% Triton X-100 (Sigma-Aldrich), and incubated for 1 h with the indicated primary anti-
bodies. Cells were then thoroughly washed with PBS and incubated for 30 min with AlexaFluor488-conjugated 
secondary antibody (Life Technologies Invitrogen Corporation). Actin was stained using phalloidin-TRITC 
(Jackson ImmunoResearch Laboratories), followed by thorough washing in PBS and DAPI staining of nuclei. 
Filters were mounted on microscope slides with Vectashield (Vector Laboratories), covered with coverslips and 
sealed. Images were recorded on a Leica TCS-SPE confocal microscope and assembled into figures with Adobe 
Photoshop software.
Statistical Analysis. Quantitative results are shown as means ± SEM of at least three independent observa-
tions. To compare sets of data, we used either ANOVA followed by Tukey’s test (for multiple treatments) or two 
tailed Student’s t tests (paired comparisons), and considered significant differences when p values < 0.05. In the 
halide-sensitive YFP-based functional assay, the signal decay caused by YFP fluorescence quenching was fitted to 
an exponential decay function to derive the maximal slope that corresponds to initial influx of I− into the cells21,23. 
Maximal slopes were converted into rates of variation of the intracellular I− concentration (in μM/s) using the 
equation d[I−]/dt = Kd [d(F/F0)/dt], where Kd is the affinity constant of YFP for I− 21,23, and F/F0 is the ratio of the 
cell fluorescence at a given time versus the initial fluorescence.
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